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Abstract
Uptake through the Dopamine Transporter (DAT) is the primary mechanism of terminating dopamine signaling within the
brain, thus playing an essential role in neuronal homeostasis. Deregulation of DAT function has been linked to several
neurological and psychiatric disorders including ADHD, schizophrenia, Parkinson’s disease, and drug addiction. Over the last
15 years, several studies have revealed a plethora of mechanisms influencing the activity and cellular distribution of DAT;
suggesting that fine-tuning of dopamine homeostasis occurs via an elaborate interplay of multiple pathways. Here, we
show for the first time that the bc subunits of G proteins regulate DAT activity. In heterologous cells and brain tissue,
a physical association between Gbc subunits and DAT was demonstrated by co-immunoprecipitation. Furthermore, in vitro
pull-down assays using purified proteins established that this association occurs via a direct interaction between the
intracellular carboxy-terminus of DAT and Gbc. Functional assays performed in the presence of the non-hydrolyzable GTP
analog GTP-c-S, Gbc subunit overexpression, or the Gbc activator mSIRK all resulted in rapid inhibition of DAT activity in
heterologous systems. Gbc activation by mSIRK also inhibited dopamine uptake in brain synaptosomes and dopamine
clearance from mouse striatum as measured by high-speed chronoamperometry in vivo. Gbc subunits are intracellular
signaling molecules that regulate a multitude of physiological processes through interactions with enzymes and ion
channels. Our findings add neurotransmitter transporters to the growing list of molecules regulated by G-proteins and
suggest a novel role for Gbc signaling in the control of dopamine homeostasis.
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Introduction
Termination of dopamine (DA) neurotransmission is accom-
plished primarily through a plasma membrane sodium-dependent
re-uptake process mediated by the dopamine transporter (DAT).
The physiological contribution of DAT to the control of DA
homeostasis has been suggested by decades of pharmacological
studies and further substantiated by genetic approaches [1]. DAT
gene deletion in mice leads to profound neurochemical changes
characterized by a 95% decrease in total DA levels [2]. Indeed,
depletion of DA stores in DAT knock-out mice was observed
despite the fact that the DA synthesis rate was elevated by two-
fold, suggesting a major role for the transporter in both the
termination of DA signaling and vesicular DA replenishment.
Because DAT plays a critical role in the control of DA
homeostasis, much attention has been placed on mechanisms
regulating DAT activity and trafficking. Signaling pathways
involved in rapid regulation of DAT include the activation of G
protein-coupled receptors, intracellular second messenger systems,
and the effect of protein-protein interactions [3–6]. As a conse-
quence, these multiples modes of regulation result in dynamic
changes in DAT function, which are expected to have profound
consequences in DA transmission and DA-related behaviors.
We recently identified the synaptic vesicle protein synaptogyrin-
3 as a DAT interacting protein [7]. The physical interaction
between synaptogyrin-3 and DAT increases transporter activity
and suggests a model in which the plasma membrane DA uptake
process is physically and functionally coupled with vesicle mono-
amine transporter 2 (VMAT2)-mediated synaptic vesicle refilling.
In this scenario, a macromolecular complex involving DAT,
synaptogyrin-3, and VMAT2 would ensure a rapid and efficient
transport of DA from the extracellular space into synaptic vesicles.
Given the functional interaction between these two transporter
systems, it is then tempting to speculate that DAT and VMAT2
might be regulated through similar signaling pathways.
VMAT2-mediated DA transport into synaptic vesicles has been
shown to be regulated by G proteins [8]. Specifically, the synaptic
vesicle-associated G protein Gao2 decreases VMAT2-mediated
vesicular DA uptake, although it is not known whether this effect is
the result of a direct interaction between the vesicular transporter
and the G protein. Interestingly, the reduction of VMAT2 activity
PLOS ONE | www.plosone.org 1 March 2013 | Volume 8 | Issue 3 | e59788
by G proteins was dependent on the vesicular content of
monoamines [9]. Site-directed mutagenesis identified the first
luminal domain of VMAT2 as being responsible for the G protein
down-regulation, leading the authors to propose this domain as
a monoamine level sensor regulated by Gao2 subunits. Because G
subunits are associated with synaptic vesicles [10], this mode of
regulation appears to be G protein-coupled receptor-independent.
Motivated by these provocative findings describing a functional
interaction between VMAT2 and synaptic vesicle-associated G
proteins, we examined the possibility that DAT-mediated uptake
might also be regulated by G proteins. In the present study, we
identify a novel interaction between DAT and Gbc subunits that
result in modulation of DAT activity.
Materials and Methods
Cell Culture and Transfections
HEK293 cells were obtained from the American Type Culture
Collection. HEK293 cells were cultured in MEM supplemented
with 10% fetal bovine serum (FBS), 1 mM glutamine, and 50 mg/
ml each penicillin and streptomycin at 37uC in a humidified, 5%
CO2 incubator. MN9D cells were provided by Dr. Alfred Heller
(University of Chicago, Chicago, IL) and maintained in DMEM
high glucose, supplemented with 10% FBS, at 37uC in a humid-
ified, 5% CO2 incubator. The human DAT cDNA was cloned
into pcDNA3.1(+) using KpnI and XbaI sites and used to transfect
HEK293 or MN9D cells with Lipofectamine 2000 (Invitrogen)
combined with a CombiTag Magneto transfection reagent (OZ
Biosciences). DAT-expressing single clones (HEK293-DAT or
MN9D-DAT cells) were selected with G418 (Gibco), verified by
DAT immunoblot and immunofluorescence, and maintained in
appropriate media containing 0.5 mg/ml G418. Cells were
transiently transfected using Lipofectamine 2000 (Invitrogen).
Immunoprecipitations and Western Blot Analysis
C57BL/6 mice were purchased from Jackson Laboratories,
whereas DAT knockout mice tissue was a generous gift from Dr.
Marc Caron (Duke University). All procedures were carried out in
accordance with the National Institute of Health’s Guide to the
Care and Use of Laboratory Animals, and were approved by the
University of Pittsburgh’s Institutional Animal Care and Use
Committee (IACUC) (Protocol number: IC-IS00000171-1) and in
the case of DAT knockout mice brain samples, procedures were
approved by the Duke University IACUC (Protocol number:
A183-10-07). Striatum and cerebellum from wild-type and DAT
knockout mice, HEK293-DAT, MN9D-DAT, or control cells
were lysed in buffer containing (in mM): 20 HEPES, 125 NaCl, 1
EDTA, 1 EGTA and 10% glycerol containing protease inhibitors.
After homogenization, 1% Triton X-100 was added, incubated for
1 h at 4uC, and centrifuged at 120006g for 15 min at 4uC to
remove cellular debris. Protein concentration was determined
using the Dc Protein Assay kit (Bio-Rad Laboratories). Immuno-
precipitations were carried out using 1 mg of total protein as
described previously [7]. Two different DAT antibodies were used
for immunoprecipitations; DAT1 (Mab369, Millipore), DAT2 (H-
80, Santa Cruz). Immunoblotting was performed with a third
DAT antibody, DAT3 (c-20, Santa Cruz) and a Gb pan-antibody
(T-20, Santa Cruz).
GST Fusion Protein Pull-down Assays, Western Blot, and
Immuno-Far Western Blot
cDNA fragments coding for intracellular domains of DAT were
amplified by PCR and subcloned into the pGEX4T-1 vector.
Plasmids construction, sequencing, and characterization have
been described previously [11]. We generated three Gluthatione-
S-Transferase (GST) fusion proteins: (1) GST-DATN (amino acids
1 to 60); (2) GST-DATL, (amino acids 119–139); and (3) GST-
DATC (amino acids 582–620) of DAT. For pull-down experi-
ments, 5–20 mg of GST fusion proteins were incubated with
striatum lysates for 30 min at 22uC. GST fusion proteins and
subsequent interacting proteins were isolated with 40 ml of
Gluthatione-resin and samples were analyzed by SDS-PAGE
and Western blotting. Direct interactions were examined by
Immuno-Far Western. Briefly, 5 mg of GST fusion proteins were
loaded into SDS-PAGE gels and electro-transferred to nitrocellu-
lose membranes. Membranes were then washed, blocked over-
night with PBS containing 1% BSA and 0.05% Tween-20, and
incubated with purified Gbc protein from bovine brain (EMD
Biosciences) for 30 min. After washing membranes with 50 mM
Tris, 150 mM NaCl, pH 8.0 four times, Western Blot was
performed with specified antibodies.
[3H]-DA and [3H]-Glutamate Uptake in Xenopus laevis
Oocytes
Capped RNAs (cRNA) encoding human DAT or human
excitatory amino acid transporter 1 (EAAT1) were synthesized
from SmalI-linearized pOTV-hDAT or pOTV-hEAAT1 using
a MESSAGE machine kit (Ambion). Synthesized cRNA was
resuspended in 10 ml of water and stored in 2 ml aliquots at
280uC until use. 50 nl of cRNA was injected into Xenopus laevis
oocytes using a nanoliter injector (nanoliter 2000, World Precision
Instruments), and oocytes were kept at 18uC in ND-96 buffer (in
mM: 96 NaCl, 4 KCl, 0.3 CaCl2, 1 MgCl2 and 5 Hepes, pH 7.4)
supplemented with 2.5 mM sodium pyruvate and 100 mg/ml
gentamycin sulfate. Experiments were performed 2–3 days after
cRNA injection. Intracellular injections of 50 nl of 100 mM GDP-
b-S or GTP-c-S (Sigma-Aldrich) were performed 15 min before
the uptake experiment. Control experiments were performed with
intracellular injections of H2O. After treatment with GTP analogs,
oocytes were incubated for 10 min in 1 ml of ND-96 buffer
containing 0.2 mM of [3H]-DA and 9.8 mM of DA or 0.2 mM of
[3H]-Glutamate (PerkinElmer). Oocytes were transferred to non-
radioactive ND-96 buffer, and washed three more times with ice-
cold stop solution. Individual oocytes were lysed with 1 ml of 1%
SDS for at least 1 h before adding the scintillation counting
solution. For experiments with the mSIRK peptide, oocytes
expressing DAT or EAAT1 were incubated for 30 min with ND-
96 solution containing 10 mM of the peptide or 0.1% DMSO as
control.
[3H]-DA Uptake Assay in Cell Lines
The conditions to examine DAT-mediated uptake in cultured
cells have been described previously [12]. Briefly, 72–96 h after
transfections, medium was removed, and DAT-mediated uptake
was measured after incubation of cells for 5 min with 250 ml of
uptake buffer (in mM: 5 Tris base, 7.5 HEPES, 120 NaCl, 5.4
KCl, 1.2 CaCl2, 1.2 MgSO4, 1 ascorbic acid, and 5 glucose,
pH 7.4). For HEK293-DAT cells, 20 nM of [3H]DA (3,4-[7-3H]
dihydroxyphenylethylamine) (34.8 Ci/mmol; PerkinElmer) and
increasing concentrations of cold DA ranging from 0.1 mM to
30 mM were used. After rinsing with 1 ml of NaCl-free uptake
buffer, cells were solubilized in 0.5 ml of 1% SDS and the
radioactivity incorporated into the cells was measured by liquid
scintillation counting. Nonspecific uptake was determined in the
presence of 300 mM cold DA. Data are presented as the mean 6
SE. For experiments with the impermeable GTP analog GTP-c-S,
HEK293-DAT cells were permeabilized with streptolysin-o (SLO,
Sigma) according to the method described in [13] with some
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modifications. Briefly, cells were incubated for 15 min at 37uC in
Hank’s Balance Salt solution (HBSS) (in mM: 137 NaCl, 5.4 KCl,
0.25 Na2HPO4, 0.44 KH2PO4, 1.0 MgSO4, 4.2 NaHCO3, 5
Glucose, and 30 HEPES, pH 7.2). Cells were incubated for
20 min at 37uC with 100 ng/ml SLO containing 50 mMGTP-c-S
and 1 mM Dithiotrietol, followed by incubation with ice-cold
HBSS containing 1.4 mM CaCl2 and 30 mM HEPES for 2 h. In
other experiments, cells were incubated with the mSIRK peptide
(myr-SIRKALNILGYPDYD) (EMD Chemicals) or the scramble
version (scb-mSIRK) (myr-SLYRLISLAPRGDYD) (Neo-
BioScience) prior to uptake. In these experiments, control cells
were incubated with 0.1% DMSO. Uptake was normalized to
protein concentrations determined using the Dc protein assay kit.
Biotinylation Assay
Transfected cells were washed three times with PBS and then
incubated with gentle agitation for 30 min at 4uC with 1 ml of
1.5 mg/ml sulfo-NHS-SS-biotin prepared in Biotinylation buffer
(in mM: 150 NaCl, 2 CaCl2, 10 triethanolamine, pH 7.8). The
reaction was quenched by incubating the cells for an additional
10 min with 50 mM glycine in PBS. Cells were then washed with
PBS and incubated in radioimmune precipitation assay buffer
(RIPA) (in mM, 10 Tris, 150 NaCl, 1 EDTA, 0.1% SDS, 1%
Triton X-100, and 1% sodium deoxycholate, pH 7.4) at 4uC for
1 h. Each sample was divided into two aliquots. One aliquot was
used for isolation of biotinylated proteins with ultralink-immobi-
lized avidin beads (Pierce). The second aliquot was used to
determine total DAT levels. Samples were analyzed by SDS-
PAGE and Western blotting with the anti-DAT antibody
(MAB369, Millipore) and an HRP-conjugated secondary antibody
(Jackson Immunoresearch Lab). Densitometry analysis of bands
was performed with ImageJ software (U.S. National Institutes of
Health).
[3H]-DA Uptake in Synaptosomes
Synaptosomes were prepared from rat striata as described [14].
Striatal synaptosomes were preincubated with various concentra-
tions of mSIRK or scb-mSIRK (0.01 mM-100 mM) at 34uC for
10 min followed by the addition of [3H]-DA (final concentration,
0.1 mM) for 8 min. Data are expressed as percentage of control
values (2020562065 dpm). Nonspecific [3H]-DA uptake was
determined in the presence of 10 mM nomifensine. Kinetic
analysis of the synaptosomal [3H]-DA uptake was determined in
the absence (control) or presence of 5 mM mSIRK. Synaptosomes
were preincubated with or without mSIRK at 34uC for 10 min
followed by the addition of one of eight mixed concentrations of
the [3H]-DA. In parallel, nonspecific uptake at each concentration
of [3H]-DA in the presence of 10 mM nomifensine, was subtracted
from total uptake to calculate DAT-mediated uptake.
In vivo Electrochemical Recordings of Striatal DA
Clearance
Clearance of exogenously applied DA from the striatum of
anesthetized male C57Bl/6 mice was measured by high-speed
chronoamperometry using the FAST-12 system (Quanteon) as
previously described [15]. All procedures involving the use of mice
were approved by the University of Texas Health Science Center
at San Antonio IACUC (Protocol number 020146). Carbon fiber
electrodes were coated with NafionH (Aldrich Chemical Compa-
ny). Neither peptide (mSIRK nor scrambled) elicited an electro-
chemical signal in vitro or in vivo. The center-to-center distance
between the microelectrode and the micropipette ejector was
,200 mm. The micropipette was filled with DA (200 mM),
mSIRK, or scrambled peptide (both 100 mM). The electrode/
micropipette assembly was lowered into the striatum (in mm from
bregma: A/P, +1.1; M/L, 61.4; D/V, 22.25). Drug application
was accomplished using a Picospritzer II (Parker Hannifin
Corporation) in an ejection volume of ,20 nl for DA to deliver
,4 pmol and attain signals at the recording electrode in the range
of 0.5 to 1.0 mM, and 50 nl for peptides to deliver 5 pmol (5–
25 psi for 0.25–3 s) with an estimated concentration of peptide
reaching the recording electrode in the range of 0.5–10 mM [16].
Oxidation potentials consisting of 100 ms pulses of 550 mV each
separated by a 1 s interval during which the resting potential was
maintained at 0 mV were applied to the microelectrode with
respect to an Ag/AgCl reference electrode implanted into the
contralateral superficial cortex. Oxidation and reduction currents
were digitally integrated during the last 80 ms of each 100 ms
voltage pulse. For each recording session, DA was pressure-ejected
at 5 min intervals until reproducible signals were obtained.
Data Analysis
Functional experiments and densitometry data were analyzed
with SigmaPlot (Systat Software Incorporation). Data are pre-
sented as the mean of at least three independent experiments with
the standard error of the mean (S.E.M.) value. For uptake
experiments, the Vmax and Km values were estimated by fitting the
data to the Michaelis-Menten equation and represent the means
from three independent experiments 6 S.E.M. Statistics for
uptake experiments were performed using a non-paired t-test with
an accepted significance level at p,0.05. In vivo clearance was
analyzed with ANOVA followed by Bonferroni or Newman-Keuls
post-hoc comparisons.
Results
Physical Interaction between DAT and Gbc Subunits
To begin to investigate the possibility that G proteins regulate
DAT activity, we first examined whether there is a physical
association between the transporter and the subunits of G proteins.
We generated three lines of evidence supporting a physical
interaction between DAT and G protein bc subunits. First,
immunoprecipitations with two antibodies directed against differ-
ent DAT epitopes resulted in co-precipitation of Gbc subunits
from mouse striatum, while no bands were detected in samples
precipitated using the corresponding control IgGs (Figure 1A). In
mouse cerebellum or striatal tissue from DAT knockout mice;
where DAT expression is not detectable, immunoprecipitation
with DAT antibodies failed to co-precipitate Gbc subunits
(Figure 1B), confirming the specificity of our DAT antibodies.
Furthermore, the DAT-Gbc interaction was recapitulated in
heterologous cells lines (MN9D and HEK293) stably expressing
human DAT (Figure 1C–D). We failed to detect any interaction
with Ga using a pan-antibody in co-immunoprecipitation
experiments (data not shown). While these results cannot rule
out the possibility of an interaction between DAT and Ga
subunits, they strongly support a physical association between the
transporter and Gbc subunits. Secondly, to identify the DAT
domains involved in the interaction with Gbc subunits, we
generated and purified three GST fusion proteins containing the
amino-terminus, the first intracellular loop, or the carboxy-
terminus of DAT (Figure 2A) and performed pull-down assays.
Only the carboxy-terminus of DAT was able to pull down Gbc
from mouse striatal lysates (Figure 2B). Finally, a direct interaction
between the carboxy-terminus of DAT and Gbc subunits was
demonstrated by Immuno-Far Western using commercially avail-
able Gbc subunits purified from bovine brain (Figure 2C). Thus,
Regulation of Dopamine Transporter by bc Subunits
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these results demonstrate a direct physical interaction between
DAT and Gbc subunits and identify the carboxy terminus of the
transporter as the site of the interaction.
Activation of G Proteins by GTP-c-S Inhibit DAT Activity
in Heterologous Systems
According to the classical model, G proteins are activated when
GTP binds to the Ga subunit of the Gabc trimeric complex,
resulting in the dissociation of the Ga from the Gbc dimer.
Subsequent hydrolysis of GTP into GDP allows the Ga and Gbc
subunits to re-associate, consequently inactivating the Gabc
complex [17]. Based on this model, we employed various
pharmacological approaches to examine the effects of G protein
activation on DA uptake. The non-hydrolyzable GTP analog
GTP-c-S binds to Ga and activates G proteins by dissociating Ga
subunits from Gbc dimers. Because GTP-c-S is cell impermeable,
we employed Xenopus laevis oocytes expressing human DAT where
the GTP analog can be injected directly into the cytoplasm.
Injection of GTP-c-S (10 mM) resulted in 30.566.1% reduction of
[H3]-DA uptake in Xenopus laevis oocytes expressing human DAT
(Figure 3A). In contrast, intracellular injection of GDP-b-S
(10 mM), which prevents Gabc complex dissociation, failed to
alter DAT uptake (Figure 3A). We repeated these experiments in
HEK293-DAT cells permeabilized with streptolysin prior to
incubation with the GTP analog GTP-c-S. As shown in
Figure 3B, GTP-c-S incubation produced a significant decrease
in DAT uptake activity, consistent with the results obtained in
oocytes. Thus, these findings suggest that the activation of
endogenous G proteins in both, Xenopus oocytes and HEK293
cells expressing DAT results in inhibition of transporter activity.
Overexpression of Gbc Subunits Inhibit DAT Activity in
Heterologous Cells
As a second functional approach, we examined the effect of
overexpressing Gbc subunits on DAT activity in HEK293 cells
stably transfected with DAT. Overexpression of Gb1c2, the most
common Gbc dimer expressed in brain, resulted in a 37.1613.8%
reduction in [H3]-DA uptake (Figure 4A). In an effort to show that
the inhibitory effect mediated by Gbc subunits is reversible, we
repeated the experiments in the presence of a Ga subunit.
Overexpression of Gai2 failed to alter DAT activity, but more
importantly prevented the inhibitory effect of Gb1c2 on DAT-
mediated uptake (Figure 4A). The changes in DAT function by
Gb1c2 overexpression were the result of a reduction in the
maximal velocity (Vmax), but not in the affinity (Km) of the
transporter for DA (Figure 4B). There are five distinct Gb
isoforms, all expressed in brain. Therefore, to investigate the
possibility that the inhibitory effect observed by Gb1c2 is isoform
specific, we repeated the experiments using the most divergent
Gb4 or Gb5 subunits. Overexpression of Gb4 or Gb5 either alone
or in combination with c2 subunits produced similar decreases in
DAT activity in HEK293 cells (Figure 4C) suggesting that the
effect is not isoform specific. Biotinylation experiments revealed
that Gb5, Gb4, or Gb1c2 overexpression resulted in no
differences in cell surface levels of the transporter compared to
control cells (Figure 4D and 4E). Thus, these results indicate that
the decrease in DAT uptake activity by Gbc subunits is not
a consequence of decreased plasma membrane levels of the
transporter.
Figure 1. Co-immunoprecipitation of DAT and Gbc subunits. (A, B) Immunoprecipitation of DAT with two DAT antibodies directed against
different DAT epitopes results in the co-precipitation of Gb subunits from mouse striatum. Control experiments include immunoprecipitations with
nonspecific rat or rabbit IgGs or immunoprecipitations from DAT knockout striatum or mouse cerebellum. (C, D) Immunoprecipitation of DAT
resulted in the co-immunoprecipitation of Gb subunits from MN9D-DAT cells or HEK293-DAT cells. Control experiments include immunoprecipita-
tions from MN9D or HEK293 mock-transfected cells. Three different DAT antibodies were used; DAT1 (Mab369, Millipore), DAT2 (H-80, Santa Cruz), and
DAT3 (c-20, Santa Cruz). Immunoblotting was performed with a Gb pan-antibody (T-20, Santa Cruz). Cereb= cerebellum, St = striatum, DAT-KO=DAT
knockout.
doi:10.1371/journal.pone.0059788.g001
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Sequestration of Endogenous Gbc Subunits Increase DAT
activity in Heterologous Cells
Next, we examined the involvement of endogenous Gbc
subunits on DAT modulation by transfecting HEK293-DAT with
either Gatransducin (Gat) or the carboxy-terminal domain of G
protein–coupled receptor kinase 2 (GRK2ct), which are both known
scavengers of Gbc subunits [18–19]. Overexpression of Gat or
GRK2ct significantly increased DAT activity (126.3%69.1% and
123.2%66.7%, respectively) (Figure 4C). These results suggest
that DAT is tonically inhibited by Gbc subunits expressed in
HEK293 cells.
Activation of Endogenous Gbc Subunits with mSIRK
Inhibit DAT Activity in Heterologous Systems
As an additional approach to assess the role of Gbc on DAT
function, we tested the effect of mSIRK, a cell-permeable
myristoylated peptide that specifically activates Gbc subunits
[20–21]. In Xenopus laevis oocytes expressing DAT, incubation with
5 mM or 25 mM of mSIRK resulted in a 34.068.0% and
57.366.3% decrease in DAT activity, respectively (Figure 5A).
To examine specificity, we tested the effect of mSIRK on
glutamate uptake in oocytes expressing the excitatory amino acid
transporter 1 (EAAT1). Here, glutamate uptake was not affected
by mSIRK under the same conditions (Figure 5A). Next, we
Figure 2. Direct interaction between Gbc subunits and the carboxy terminus of DAT. (A) Schematic representation of DAT depicting
cytoplasmic segments used in GST pull-down assays. (B) The carboxy terminus of DAT (GST-DATc) precipitated Gbc subunits from mouse striata. (C)
Immuno-far-western assay showing a direct interaction between GST-DATc and purified Gbc from bovine brain. RP= Ponceau Red.
doi:10.1371/journal.pone.0059788.g002
Figure 3. Activation of G proteins with GTP-c-S inhibits DAT function in heterologous systems. (A) [3H]-DA uptake assays in Xenopus
laevis oocytes expressing DAT after intracellular injection with water (white bar, n = 8), 10 mM GTP-c-S (black bar, n = 8), or 10 mM GDP-b-S (gray bar,
n = 8). (B) Specific [3H]-DA uptake and kinetic analysis for HEK293-DAT permeabilized with streptolysin-O (SLO) and dialyzed with 50 mM GTP-c-S
(white circles, n = 3). or control buffer (black circles, n = 3). **p,0.01.
doi:10.1371/journal.pone.0059788.g003
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repeated these experiments in HEK293-DAT cells. mSIRK pre-
incubation for 5 min produced a dose-dependent inhibition of
[H3]-DA uptake with an IC50 of 10.662.6 mM; whereas,
a scramble myristoylated peptide (scb-mSIRK) failed to alter DA
uptake (Figure 5B). Longer incubation times with mSIRK did not
augment the inhibitory effect on DAT function
(IC50 = 13.261.2 mM). Kinetic analysis revealed that mSIRK
incubation resulted in a reduction of Vmax without changes in the
Km of DAT (Figure 5C). To confirm that the effect of mSIRK is
mediated by Gbc subunits, we repeated these experiments in
HEK293-DAT cells transfected with the Gbc scavenger GRK2ct.
Consistent with our previous results (Figure 4C), overexpression of
GRK2ct in HEK293-DAT cells increased DAT activity. More
importantly, the inhibitory effect of mSIRK was significantly
attenuated in the presence of GRK2ct (Figure 5D). Thus, these
results are consistent with those obtained with GTP-c-S and Gbc
subunit overexpression and further support the contention that
activation of Gbc subunits results in inhibition of DAT activity.
Activation of Endogenous Gbc Subunits with mSIRK
Inhibit DAT Activity in Striatal Synaptosomes
To examine the Gbc-mediated regulation of DAT in native
systems, we first assessed the effect of mSIRK on DAT activity in
striatal synaptosomes. Pre-incubation of synaptosomes for 5 min
with mSIRK, but not with scb-mSIRK, resulted in a dose-
dependent inhibition of DAT activity with an IC50 of 5.460.9 mM
(Figure 6A), which is consistent with reported IC50 values for
mSIRK in other systems [20–22]. As observed with heterologous
cells, the effect of mSIRK on DAT function reflected changes in
Vmax (37.764.6% reduction) without changes in Km (Figure 6B).
Activation of Endogenous Gbc Subunits with mSIRK
Inhibit DAT Activity In Vivo
Finally, we performed high-speed chronoamperometry to
examine the in vivo effect of the mSIRK peptide on DA clearance
in striatum. In these experiments, a recording microelectrode was
placed in the striatum and a glass multi-barrel micropipette was
positioned adjacent to the electrode to locally deliver DA, mSIRK,
or scrambled peptide. For each recording session, DA was
pressure-ejected at 5 min intervals before and after mSIRK or
scrambled peptide. mSIRK application, but not scrambled peptide
produced an increase in both the amplitude of the DA signal
(Figure 7A) and the clearance time of extracellular DA (Figure 7B).
This pattern is consistent with an inhibition of DAT uptake
activity, which is typically observed with known inhibitors of DA
transport [15]. Taken together, our findings from synaptosomal
preparations and intact animals provide compelling evidence that
G protein bc subunits modulate DAT activity within a physiolog-
ical context.
Discussion
Here, we have used a combination of biochemical and
functional approaches in heterologous systems, brain synapto-
somes, and in vivo to demonstrate that Gbc subunits regulate DAT
activity. Biochemically, we provide evidence for a direct in-
teraction between DAT and Gbc through co-immunoprecipita-
Figure 4. Overexpression of Gbc subunits results in decreased DAT uptake activity in HEK-293-DAT cells. (A, B) Specific [3H]-DA uptake
and kinetic analysis for HEK293-DAT control cells (white bar, n = 6) or transfected with Gb1c2 (n = 3), Gai2 (n = 3), or Gai2Gb1c2 (n = 3). (C)
Overexpression of Gb4 (n = 5) or Gb5 (n = 7) (gray bars), decreased [3H]-DA uptake in HEK293-DAT cells when compared to control (white bar, n = 19).
Overexpression of the Gbc scavengers (black bars), Gat (n = 6), or GRK2ct (n = 4) increased [
3H]-DA uptake. (D, E) Overexpression of Gb1c2 (n = 4), Gb4
(n = 5), or Gb5 (n = 7) in HEK-DAT cells did not alter the plasma membrane levels of DAT as measured by biotinylation. T = total fraction,
B =biotinylated fractions, **p,0.01.
doi:10.1371/journal.pone.0059788.g004
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tion and pull-down assays with purified proteins. Functionally,
Gbc subunit activation by multiple approaches resulted in a rapid
inhibition of transporter activity without alterations in levels of the
transporter at the cell membrane. To our knowledge, no data are
available describing an interaction between plasma membrane
neurotransmitter transporters and G proteins and thus, this is the
first study to identify a Gbc-mediated modulation of a neurotrans-
mitter transporter.
According to the traditional view, upon binding of an
extracellular agonist to a G-protein coupled receptor (GPCR), G
proteins dissociate into active Ga and Gbc subunits. Originally,
the Ga subunits were believed to transduce cellular responses,
while the Gbc subunits were regarded to function solely as
negative regulators of Ga-mediated signaling. Investigations over
the last 20 years have revealed that the activation and function of
G proteins is far more complex than previously anticipated. There
Figure 5. Activation of Gbc with mSIRK resulted in an inhibition of DAT activity in heterologous systems. (A) Oocytes expressing DAT
(white bars) or EAAT1 (gray bars) were incubated for 30 min with 0.5% DMSO (DAT/n= 3; EAAT1/n= 25), 5 mM mSIRK (DAT/n= 20, EAAT1/n= 23), or
25 mMmSIRK (DAT/n= 15, EAAT1/n= 15) before uptake assays with [H3]-DA or [3H]-Glutamate, respectively. (B) Dose-dependent inhibition of [3H]-DA
uptake in HEK293-DAT cells by mSIRK (n = 4, white circle). (C) 5 min pre-incubation of HEK293-DAT cells with 10 mM mSIRK produced a reduction of
Vmax with no changes in Km (n = 3). (D) In HEK293-DAT, 10 mM mSIRK reduced uptake (control, black bar, n = 32; mSIRK, white bar, n = 15). The
inhibitory effect of 10 mM mSIRK was attenuated in HEK-DAT cells expressing GRK2ct (control, n = 16; mSIRK, n = 16). **p,0.01 or *p,0.05.
doi:10.1371/journal.pone.0059788.g005
Figure 6. Activation of Gbc subunits reduces DAT activity in brain synaptosomes (A) mSIRK reduces [3H]-DA uptake in rat striatal
synaptosomes. Samples were pre-incubated for 10 min with various concentrations of mSIRK (open circles) or scb-mSIRK (filled circles) at 34uC,
followed by the addition of [3H]-DA (final concentration, 0.1 mM) for 8 min, n = 3. Nonspecific [3H]-DA uptake was determined in the presence of
10 mM nomifensine. (B) Kinetic analysis of the synaptosomal [3H]-DA uptake was determined in the absence (vehicle) or presence of 5 mM mSIRK,
n = 3. **p,0.01.
doi:10.1371/journal.pone.0059788.g006
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is now evidence for both, receptor-dependent and -independent
Ga- and Gbc-mediated responses [23]. In the case of VMAT2,
the Ga-mediated inhibition of the transporter appears to be
receptor-independent as Ga subunits are associated with synaptic
vesicles [8], [10]. Our findings from immunoprecipitation
experiments and those using Gbc subunits scavengers suggest
a receptor-independent regulation, however, we can’t rule out
a receptor-mediated regulation of DAT activity through Gbc
subunits. Potential GPCRs expressed in DA neurons, which could
modulate DAT activity include receptors for glutamate, norepi-
nephrine, serotonin, ATP, and DA. Indeed, several studies have
documented changes in DAT activity as a result of the activation
of D2 DA receptors (D2R) [24–25]. Interestingly, recent pro-
vocative evidence suggests that the dopamine D2 receptor (D2R)
regulates the trafficking of DAT to the plasma membrane through
a direct protein-protein interaction [26]. Together, the available
data suggest up-regulation of DAT through two mechanisms
involving the activation of second messenger systems through D2R
[25], as well as a direct protein-protein interaction between D2R
and DAT [26]. Thus, it is unlikely that the Gbc-dependent
decrease in DAT activity is related to activation of D2R. Future
studies will be required to examine whether the Gbc-mediated
inhibition of DAT described in this report is related to the
activation of additional GPCRs or represents a receptor-in-
dependent mechanism.
Additionally, evidence has accumulated indicating that Gbc
subunits also transduce cellular signals. In fact, Gbc subunits
have been reported to directly regulate a diverse array of
effector molecules including ion channels, enzymes, and in-
tracellular regulators [27]. These interactions provide a role for
Gbc in important physiological functions such as cardiac
membrane potential, heart rate, inflammation, pain modulation,
and neurotransmitter release [17], [28–29]. Of the many
identified Gbc effectors, the Gbc-mediated inhibition of
voltage-dependent calcium channels has been one of the most
widely studied and best characterized [30]. Gbc directly binds
and inhibits calcium channel activity. Likewise, Gbc has also
been reported to interact with syntaxin 1A [31], which is part
of a SNARE protein complex that links the calcium channel to
the vesicular release machinery. These findings suggest a com-
plex interplay between the channel, G proteins, and SNARE
proteins that modulate neurotransmitter release. Based on this
model, we speculate that a similar network may exist between
DAT, Gbc, and synaptic vesicles. Indeed, we previously
reported that DAT is also physically and functionally coupled
to synaptic vesicles via an interaction with synaptogyrin-3 [7].
Further supporting this idea, syntaxin 1A has also been reported
to interact and modulate DAT [32–34]. Future studies will be
needed to explore this possibility.
Despite the fact that there is much to learn regarding the
modulation of DAT by Gbc subunits, the identification of DAT
as a novel Gbc effector will open new avenues to our
understanding of DA homeostasis regulation. DAT plays
a crucial role in the control of DA homeostasis and has been
implicated in a variety of psychiatry disorders and drug
addiction [35]. Our findings suggest a novel mechanism for
the control of DA homeostasis and may introduce a novel target
for treatment of DA-related disorders. It remains to be seen
whether additional plasma membrane transporters such as the
norepinephrine, serotonin, GABA, or glutamate transporters are
also modulated by G proteins.
Acknowledgments
We are grateful to the Torres and Amara laboratories for helpful
discussions. We also thank Dr. Marc Caron and Ms. Wendy Roberts (Duke
University) for providing DAT knockout tissue and Dr. Luis Aguayo
(Universidad de Concepcion, Chile) for providing cDNAS expressing
b subunits and GRK2ct.
Figure 7. Activation of Gbc subunits reduces DAT activity in vivo. (A) Clearance of exogenously applied DA from the striatum of anesthetized
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